Holmes C, Ballard C, Lehmann D, David Smith A, Beaumont H, Day I N, Nadeem Khan M, Lovestone S, McCulley M, Morris C M, Munoz D G, O'Brien K, Russ C, Del Ser T, Warden D
University of Southampton, Clinical Neurosciences Research Division, Memory Assessment and Research Centre, Moorgreen Hospital, Botley Road, Southampton, UK.
J Neurol Neurosurg Psychiatry. 2005 May;76(5):640-3. doi: 10.1136/jnnp.2004.039321.
To determine whether individuals with Alzheimer's disease (AD) and the K variant allele of butyrylcholinesterase have a slower rate of cognitive decline than those without the K variant allele of butyrylcholinesterase.
The cognitive status of 339 community based subjects with AD was assessed with the Mini Mental State Examination at baseline and yearly over a three year follow up period. The rates of cognitive decline of subjects with and without the K variant allele were compared.
Presence of the K allele was associated with a slower average rate of cognitive decline in subjects with severe AD.
This finding is consistent with the suggestion that the K variant of butyrylcholinesterase has an important role in disease progression in AD, and this may have implications for treatment.
确定患有阿尔茨海默病（AD）且携带丁酰胆碱酯酶K变异等位基因的个体，其认知衰退速度是否比未携带丁酰胆碱酯酶K变异等位基因的个体更慢。
对339名社区AD患者的认知状态在基线时进行简易精神状态检查表评估，并在三年随访期内每年评估一次。比较携带和未携带K变异等位基因的受试者的认知衰退率。
K等位基因的存在与重度AD患者较慢的平均认知衰退率相关。
这一发现与丁酰胆碱酯酶K变异在AD疾病进展中起重要作用的观点一致，这可能对治疗有影响。
